Phylogeny, Columbus, Ohio, and Neoprobe, Dublin, Ohio, have announced that they are collaborating on the development of Neoprobe’s Lymphoseek , a new imaging agent for the detection of head and neck cancers.

Neoprobe is currently in Phase III clinical trials to determine the efficacy of Lymphoseek, which is intended to improve the imaging and the detection of cancer cells within the lymphatic system.

Phylogeny will evaluate Lymphoseek’s accuracy in detecting metastatic cells and act as a central pathology lab for Neoprobe’s clinical trial.

Neoprobe has additionally contracted with The Ohio State University for clinical studies and with Cardinal Health for the eventual distribution of Lymphoseek.

Contact Phylogeny or Neoprobe for more information.

(Source: Press Release)